| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.19 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.02 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |